Published in Top HIV Med on April 28, 2008
The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res (2009) 1.93
The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol (2008) 1.31
Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv (2009) 1.05
CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB J (2009) 0.97
Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr Med Chem (2014) 0.94
Massive cerebral edema resulting in brain death as a complication of Cryptococcus neoformans meningitis. J Community Hosp Intern Med Perspect (2015) 0.87
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc (2004) 6.64
Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol (2004) 3.12
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis (2011) 2.44
Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry (2005) 2.34
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol (2002) 2.28
Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol (2007) 2.27
Neurologic complications of HIV disease and their treatment. Top HIV Med (2010) 2.14
Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS (2006) 2.13
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS (2007) 2.09
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis (2003) 2.04
Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol (2007) 2.03
Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS (2002) 1.78
A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr (2007) 1.76
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol (2011) 1.73
Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS (2013) 1.71
Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol (2004) 1.65
Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol (2005) 1.62
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol (2009) 1.57
Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord (2007) 1.56
The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS (2005) 1.55
Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis (2004) 1.54
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS (2004) 1.53
Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS (2013) 1.51
Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr (2005) 1.47
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage (2004) 1.40
HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis (2010) 1.40
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS (2009) 1.40
Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci (2007) 1.39
The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS (2002) 1.38
HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurol (2010) 1.31
Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol (2011) 1.31
Neurocognitive functioning in acute or early HIV infection. J Neurovirol (2010) 1.27
HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS (2007) 1.25
Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol (2003) 1.22
Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol (2004) 1.21
Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care (2012) 1.21
Psychiatric context of acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: IV. AIDS Behav (2009) 1.20
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother (2010) 1.19
Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. J Acquir Immune Defic Syndr (2005) 1.16
Lithium improves HIV-associated neurocognitive impairment. AIDS (2006) 1.16
Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr (2011) 1.16
Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr (2003) 1.15
Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol (2006) 1.14
Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care (2011) 1.13
Neurologic complications of HIV disease and their treatment. Top HIV Med (2009) 1.13
Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol (2008) 1.12
A battery approach for measuring neuropsychological change. Arch Clin Neuropsychol (2005) 1.11
Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol (2007) 1.10
A neuropsychological investigation of multitasking in HIV infection: implications for everyday functioning. Neuropsychology (2011) 1.09
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol (2008) 1.08
Measuring medication: do interviews agree with medical record and pharmacy data? Med Care (2002) 1.06
HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence. AIDS Behav (2012) 1.06
Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc (2003) 1.06
Lifetime suicidal ideation and attempt are common among HIV+ individuals. J Affect Disord (2011) 1.06
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis (2013) 1.05
Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil. J Neurovirol (2013) 1.05
Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use. J Addict Med (2013) 1.04
Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol (2012) 1.03
The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr (2014) 1.03
The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther (2004) 1.02
Role of metabolic syndrome components in human immunodeficiency virus-associated stroke. J Neurovirol (2009) 1.01
Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria. J Neurovirol (2012) 1.00
Implications of apathy for everyday functioning outcomes in persons living with HIV infection. Arch Clin Neuropsychol (2012) 0.99
Physical exercise is associated with less neurocognitive impairment among HIV-infected adults. J Neurovirol (2013) 0.99
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother (2010) 0.98
Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS. J Neuroimmune Pharmacol (2007) 0.98
Osteopontin is increased in HIV-associated dementia. J Infect Dis (2008) 0.98
Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons. J Acquir Immune Defic Syndr (2013) 0.95
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr (2012) 0.95
Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS (2009) 0.95
Pleocytosis is associated with disruption of HIV compartmentalization between blood and cerebral spinal fluid viral populations. Virology (2008) 0.94
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS (2009) 0.94